SD 1 plse-20220531corresp.htm FORM SD Form SD

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

____________________

FORM SD

Specialized Disclosure Report

____________________

Pulse Biosciences, Inc.

(Exact name of registrant as specified in its charter)

____________________

 



 

 

 

 

Delaware

 

001-37744

 

46-5696597

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

3957 Point Eden Way

Hayward, California 94545

(Address of principal executive offices, including zip code)

Sandra A. Gardiner

Chief Financial Officer, Executive Vice President of Finance

and Administration, and Treasurer

(510) 906-4600

(Name and telephone number, including area code, of the person to contact in connection with this report)



____________________

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:





 

 

 

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2021





 


 

Section 1.    Conflict minerals disclsosure 



Item 1.01 Conflict Minerals Disclosure and Report 

A copy of Pulse Biosciences, Inc.’s (the Company’s) Conflict Minerals Report for the reporting period January 1, 2021 to December 31, 2021 is provided as Exhibit 1.01 hereto and is publicly available at www.pulsebiosciences.com.

Item 1.02 Exhibit 

In accordance with Rule 13p-1, and this Form SD, the Company is hereby filing its Conflict Minerals Report for the calendar year ended December 31, 2021 as Exhibit 1.01 to this report.



Section 2.    Exhibits 

The following exhibits are filed as part of this report:



Item 2.01 Exhibits 

Exhibit 1.01 — 2021 Conflict Minerals Report of Pulse Biosciences, Inc. as required by Items 1.01 and 1.02 of this Form SD.












 

SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





 

 



Pulse Biosciences, Inc.



 

 



By:  

/s/ Sandra A. Gardiner



 

Sandra A. Gardiner

Chief Financial Officer, Executive Vice President of Finance and Administration, and Treasurer

(Principal Financial and Accounting Officer)



Date: May 31, 2022